[Gastrointestinal stromal tumors : Where do we stand?] / Gastrointestinale Stromatumoren : Wo stehen wir?
Pathologie (Heidelb)
; 45(3): 223-232, 2024 May.
Article
in De
| MEDLINE
| ID: mdl-38587549
ABSTRACT
For more than 20 years gastrointestinal stromal tumors (GIST) have been a paradigm for a targeted treatment with tyrosine kinase inhibitors. A fundamental prerequisite for a neoadjuvant or adjuvant treatment of localized GIST or an additive treatment of metastatic GIST is the molecular typing of tumors, ideally at the initial diagnosis. In addition, the possibility of a hereditary or syndromic predisposition must be considered because this results in consequences for the treatment and a different follow-up strategy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gastrointestinal Stromal Tumors
Limits:
Humans
Language:
De
Journal:
Pathologie (Heidelb)
Year:
2024
Document type:
Article